Immutrin Raises $87 Million to Advance ATTR-CM Therapy

Rare Daily Staff

U.K.-based Immutrin raised $87 million (£65 million) in an oversubscribed series A financing to advance a next-generation antibody therapy for transthyretin amyloid cardiomyopathy, a rare disease that can lead to heart failure and other serious cardiovascular events.

Frazier Life Sciences led the round, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures.

The company said it will use the funding to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy, a serious and often fatal form of amyloidosis. The disease is caused by misfolded proteins that form amyloid fibrils and accumulate in tissues and organs, leading to progressive and irreversible damage.

Immutrin is developing an antibody designed to selectively bind to amyloid fibrils and trigger a targeted immune response to remove established deposits. While existing therapies can slow or suppress amyloid production, there are currently no approved treatments that effectively clear preexisting deposits.

The company was founded by Cambridge Innovation Capital and academic leaders including Mark Pepys, Nobel laureate Gregory Winter, and Daniel Christ, whose work underpins the antibody-based strategy.

As part of the financing, James Topper, managing partner at Frazier Life Sciences; Nihal Sinha, partner at F-Prime; and Alex Sinclair-Wilson, principal at Qiming Venture Partners, will join the board of directors alongside Tuna, Chair Sef Kurstjens, and Michael Anstey of Cambridge Innovation Capital.